STERIS (STE) Financials

STERIS plc (NYSE: STE) has delivered a generally solid operating performance over the last several years, with revenue steadily rising and operating profit remaining resilient. The latest quarter, however, shows some signs of margin pressure and heavier use of financing, even as cash generation remains healthy.

• Revenue trend remains positive. Quarterly revenue has grown from about $1.16 billion in Q1 2023 to $1.59 billion in Q4 2026, showing steady top-line expansion over the period.
• Profitability remains strong. In Q4 2026, STERIS generated $316.8 million in operating income and $220.3 million in net income, indicating the business is still converting sales into meaningful profit.
• Operating cash flow is consistently robust. Q4 2026 operating cash flow was $335.4 million, while recent quarters have generally stayed in a healthy range, supporting financial flexibility.
• Gross profit dollars have been growing. Gross profit increased from roughly $529 million in Q1 2023 to $697.1 million in Q4 2026, reflecting a larger business scale.
• Balance sheet equity remains substantial. As of Q3 2026, total common equity was $7.15 billion on $10.59 billion of assets, giving the company a solid equity base.
• Cash has improved, but debt remains meaningful. Cash and equivalents rose to $423.7 million in Q3 2026 from $279.7 million in Q1 2026, but total debt is still sizable, with long-term debt of $1.90 billion and additional capital lease obligations.
• Capex remains consistent. STERIS continues to invest in property, plant and equipment, with quarterly capex generally around $70 million to $120 million, suggesting ongoing investment in the business.
• Dividend payments look sustainable for now. The quarterly dividend has been steady at $0.63 per share in the latest periods, supported by ongoing earnings and cash flow.
• Margins softened in the latest quarter. Q4 2026 gross margin and operating margin were lower than the prior year’s comparable quarter, as cost of revenue and operating expenses took a larger share of sales.
• Financing cash flow was a drag. In Q4 2026, financing activities used $97.9 million of cash, driven by debt activity, share repurchases, and dividends.
• Share count has drifted higher over time. Weighted average diluted shares were about 97.6 million in Q4 2026 versus roughly 96.3 million a year earlier, which can modestly dilute per-share growth.
• Debt levels are elevated versus cash. While operating performance is healthy, the company’s debt load is still much larger than its cash balance, which leaves less balance-sheet cushion than the income statement alone might suggest.

Bottom line: STERIS still looks like a fundamentally profitable and cash-generative healthcare equipment company with a positive multi-year growth trend. The main watch items are margin pressure, leverage, and ongoing capital returns, but the core business remains on solid footing.